OCGN Share Price Performance
US$1.38
0.50 (56.21%)
88.1% undervalued intrinsic discount
US$11.57
Fair Value
Price US$1.38
AnalystConsensusTarget US$11.57
AnalystHighTarget US$15.00
AnalystLowTarget US$7.00
Fair ValueUS$11.57
Share Pricen/a
Ocugen, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 93 Fair Values set on narratives written by author
OCGN Community Narratives
AN
Fair Value
·Fair Value US$11.57 88.1% undervalued intrinsic discount
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
1users have liked this narrative
1users have commented on this narrative
48users have followed this narrative
AN
Fair Value
·Fair Value US$15 90.8% undervalued intrinsic discount
Gene Therapy Catalysts Will Transform Long-Term Prospects In Retinal And Geographic Atrophy Markets
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$7 80.3% undervalued intrinsic discount
Gene Therapy Regulatory And Reimbursement Risks Will Dominate Before Long-Term Retinal Opportunity Emerges
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Key Takeaways Progress in gene therapy development and regulatory engagement positions Ocugen for faster market entry, revenue growth, and strong long-term margins. In-house manufacturing and non-dilutive partnerships boost supply chain control and reduce reliance on shareholder dilution, supporting future earnings expansion.Read more
AN
US$11.57
88.1% undervalued intrinsic discount
Fair Value
Profit Margin
17.16%
Future PE
167.18x
Price in 2029
US$14.25
Gene Therapy Catalysts Will Transform Long-Term Prospects In Retinal And Geographic Atrophy Markets
Catalysts About Ocugen Ocugen is a biotechnology company developing gene and cell therapies aimed at treating serious eye diseases and restoring vision with one time treatments. What are the underlying business or industry changes driving this perspective?Read more
AN
US$15
90.8% undervalued intrinsic discount
Fair Value
Profit Margin
18.54%
Future PE
102.05x
Price in 2028
US$18.45
Gene Therapy Regulatory And Reimbursement Risks Will Dominate Before Long-Term Retinal Opportunity Emerges
Catalysts About Ocugen Ocugen is a clinical stage biotechnology company developing one time gene therapies for inherited retinal diseases and age related eye disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
US$7
80.3% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
120.86x
Price in 2028
US$8.62
Trending Discussion
Recently Updated Narratives
AN
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Fair Value: US$11.57 88.1% undervalued intrinsic discount
48 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Catalysts Will Transform Long-Term Prospects In Retinal And Geographic Atrophy Markets
Fair Value: US$15 90.8% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Regulatory And Reimbursement Risks Will Dominate Before Long-Term Retinal Opportunity Emerges
Fair Value: US$7 80.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ocugen, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.21
- -797.94%
- -1,605.22%
- 502.9%
About OCGN
- Founded
- 2013
- Employees
- 116
- CEO
- WebsiteView website
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
